Niazi notes that GLP-1s can also result in rare but serious side effects, including pancreatitis, gallbladder disease and cholecystitis
Insurance coverage for semaglutide is tied to approved indications (type 2 diabetes for Ozempic, obesity for Wegovy), not to dose levels
Placebo nausea was 14.8%
Retatrutide is an effective triple-receptor agonist that works by slowing stomach emptying, regulating appetite, and boosting energy metabolism
Its triple agonism, including glucagon receptor activation, distinguishes it from dual-agonist tirzepatide and may provide enhanced energy expenditure and hepatic fat reduction
Melanotic neuroectodermal tumor of infancy (MNTI) are polyphenotypic neoplasms exhibiting evidence of neural, epithelial, mesenchymal, and neuroectodermal differentiation